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Background: Afatinib has demonstrated efficacy in EGFR mutationpositive (EGFRm+) NSCLC; however, resistance develops over time, most commonly due to the emergence of the T790M mutation. Osimertinib has shown clinical activity in the treatment of T790M-positive disease following progression on a first-line tyrosine kinase inhibitor. Further information on outcomes of sequencing options is necessary to optimize treatment outcomes for patients. Method: This observational study is the first to evaluate outcomes of real-world patients who sequentially received first-line afatinib followed by osimertinib. Data were retrospectively collected between December 2017 and May 2018. Patients had common EGFRm+ (Del19, L858R) advanced NSCLC and acquired T790M after first-line afatinib. Patients must have completed afatinib treatment and started osimertinib treatment 10 months prior to data entry. Patients with active brain metastases were excluded. The primary outcome was time on treatment (ToT) from initiation of afatinib until discontinuation of osimertinib. Results: A total of 204 patients were included in the study; of these, 24.5/67.6% were Asian and non-Asian (Caucasian and African American), 15.3% had ECOG performance status 2, and 73.5/26.0% were Del19/L858R-positive. Overall median ToT was 27.6 months (90% CI: 25.9e31.3). Median time on afatinib and osimertinib was 11.9 months (90% CI: 10.9e12.2) and 14.3 months (90% CI: 12.8e15.9), respectively. The 2-year OS rate was 78.9%. ToT was generally consistent across patient subgroups; however, ToT was longer in Asian patients (n¼50; median 46.7 months; 90% CI: 26.8enot reached) and in those with Del19-positive disease (n¼150; median 30.3 months; 90% CI: 27.6e44.5). Patients with poor prognosis, such as those with ECOG PS 2 (n¼31, median ToT 22.2 months; 90% CI: 16.0e27.0) and stable brain metastases (n¼21, median ToT 19.4 months; 90% CI: 16.0enot reached), also appeared to derive clinical benefit. 6.6% of patients developed brain metastases on afatinib therapy. Conclusion: First-line afatinib followed by osimertinib is a feasible therapeutic strategy in a broad, real-world patient population with EGFRm+ NSCLC and acquired T790M mutation, resulting in 27.6 months of chemotherapy-free treatment. The benefit of sequential afatinib followed by osimertinib was observed across patient subgroups, with prolonged benefit seen in some subgroups, including those with Del19-positive disease. Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo/JP Background: Patients with EGFR-mutation-positive non-small-cell lung cancer (EGFR-NSCLC) who are treated with both cytotoxic chemotherapy and EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have better survival outcomes than those who are only treated with EGFRTKIs. Limited information is available about the factors that influence the non-administration of cytotoxic chemotherapies after the failure of EGFR-TKIs. Method: We reviewed the medical records of EGFR-NSCLC patients who received EGFR-TKIs as a first-line treatment at the National Cancer Center Hospital between January 2010 and December 2016. Computed tomography data regarding the number of metastatic organs, at the time of progressive disease (PD), which reflects the tumor burden, was retrieved. EGFR-TKIs use beyond PD was also investigated. We performed a multivariate logistic regression analysis to determine the factors influencing the non-administration of cytotoxic chemotherapies. Results: A total of 393 patients received EGFR-TKIs as a first-line treatment during the study period. After the exclusion of 96 patients who were receiving ongoing EGFR-TKIs treatment, 297 patients (103 men, 194 women) were included in this analysis. The median age was 68 years (range, 33-87 years), and 291 patients had an adenocarcinoma histology; 155 had deletions in exon 19, 132 had the L858R point mutation in exon 21, and 10 had other minor mutations. An Eastern Cooperative Oncology Group performance status (PS) of 0e1, 2e4, and unknown was seen in 224, 55, and 18 patients, respectively. One-hundred and eleven patients received continued EGFR-TKIs treatment beyond PD. The number of metastatic organs at PD was evaluated, and 103 had 3 metastatic organs. Among the 297 patients included in this analysis, 177 (60%) received chemotherapy after EGFR-TKIs. A logistic regression analysis revealed that an age 70 years, a PS 2, the EGFR L858R mutation in exon 21, EGFR-TKIs use beyond PD, and 3 metastatic organs were independent factors influencing the non-administration of cytotoxic chemotherapies. Conclusion: EGFR-TKI use beyond progression, an increased number of metastatic organs, a higher age, and PS at the point of TKI failure were associated with the non-administration of subsequent cytotoxic chemotherapies. ICIs) . There is a lack of standardization for TMB estimation and reporting, which is critical for ensuring consistency for clinical implementation. An international collaboration organized by Friends of Cancer Research (Friends) and Qualitätssicherungs-Initiative Pathologie GmbH (QuIP) is establishing recommendations for achieving consistency in TMB estimation and reporting. Method: Friends and QuIP are using complementary TMB harmonization approaches. Friends will conduct in silico analyses where TCGA data will be compared between TMB estimates derived from whole exome sequencing (WES) and commercial targeted gene panels, followed by the use of patientderived tumor cell lines to establish a universal reference standard for the alignment of panel-derived estimates. QuIP will compare TMB estimates from selected tissue (NSCLC and other solid tumors) using a WES-derived reference standard with commercial next-generation sequencing panels and lab-developed tests at several German academic institutions. These data will inform consistency of TMB estimation, assay comparability, and TMB cutoff values for potential clinical use. Results: Preliminary data indicate several components influence TMB estimation: preanalytical factors (eg, input material quality/quantity), sequencing parameters (eg, enrichment technologies), library preparation, bioinformatics (eg, filtering of germline variants), FFPE-induced deamination artifacts, mutation types, and clonal vs subclonal events. Analyses of panel size and composition suggest that larger panels may yield more reliable TMB estimation and that the panel should include actionable targets, genes associated with mutagenesis (eg, microsatellite instability), and potential negative predictors of response (eg, mutated b2M, JAK1/2, PTEN Oncology Department, Vall d'Hebron University Hospital, Barcelona/ES Background: The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in w3% and 0.4e4% of NSCLCs, respectively. Tepotinib is a potent and highly selective, small molecule inhibitor of MET. Method: This single-arm, open-label, multicenter Phase 2 trial (NCT02864992) will assess the efficacy and safety of tepotinib, 500 mg once-daily as 1 st e3
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rd line of treatment, in patients with histologically confirmed, Stage IIIB/IV NSCLC harboring either METex14+ (Cohort A, detected in tumor [TBx] and/or plasma [liquid biopsy; LBx] samples) or METamp (Cohort B). Patients with epidermal growth factor receptor (EGFR)-activating mutations or anaplastic lymphoma kinase (ALK) rearrangements are excluded. Enrollment into Cohort A began in September 2016 and recruitment into this cohort is ongoing. In Cohort B, patients will initially be enrolled based on METamp via LBx. The primary endpoint is objective response rate (ORR) assessed by an independent review committee (IRC) -via Response Evaluation Criteria in Solid Tumors version 1.1. Secondary endpoints include investigator-assessed ORR, and investigator/IRC-assessed duration of response, disease control, progression-free survival, and overall survival. The tolerability and safety of tepotinib will also be assessed as secondary objectives. Burning Rock Biotech, Guangzhou/CN Background: Human epidermal growth factor 2 (HER2, ERBB2) gene alterations have been identified as oncogenic drivers in 2-5% of lung cancers. ERBB2 In-frame insertions in exon 20 (20ins) lead to constitutive activation of receptor and downstream pathways. However, response heterogeneity of different exon 20 insertions to ERBB2 inhibitor afatinib exists. In vitro and structural modeling results suggested that Glycine778 may facilitate inhibitor binding to ERBB2. In this study, our aim was to improve our understanding of clinical characteristics in ERBB2-mutated Chinese lung cancer and investigate the clinical outcomes of specific ERBB2 exon 20 insertions in response to afatinib. Method: We reviewed 7520 lung cancer patients whose tissue or plasma biopsies were sequenced in a CLIA-certified sequencing laboratory between 2015 to 2018. Clinical records of 19 patients (18 adenocarcinomas and 1 squamous cell carcinoma) with several different ERBB2 20ins after afatinib treatment were collected for clinical outcomes evaluation. Results: ERBB2 20ins were identified in 2.27% (171/7,520) in this Chinese lung cancer cohort. It occurred with a high proportion in females with adenocarcinoma histology. 11.7% (20/171) ERBB2 20ins-positive patients harbored concomitant ERBB2 amplification. Y772_A775dup (119/171, 69.6%) was the most frequently occurred 20ins subtype, followed by G778_P780dup (18/ 171, 10.5%). For the 19 patients treated with afatinib, they had a median PFS of 4.5 months and median OS of 11.5 months. The overall response rate in this cohort was 15.8% (3/19) and disease control rate was 68.4% (13/19). Next, we interrogated the clinical outcomes of specific 20ins subtype responding to afatinib. We found that patients harboring G778_P780dup (G778) achieved longer median PFS (10 vs 3.3 months, p¼0.32) and median OS (19.7 vs 7 months, p¼0.16) than non-G778 patients, consisting with in vitro results. Although statistical significance was not achieved due to limited number of G778_P780dup patients, this result warranted further investigation into this phenomenon. Moreover, to the best of our knowledge, we identified the first case of a lung squamous cell carcinoma patient harboring ERBB2 20ins from this cohort. He displayed favorable response to afatinib and achieved partial response with significant tumor shrinkage.
